<DOC>
	<DOCNO>NCT00128492</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy multiple course AZLI patient cystic fibrosis ( CF ) lung infection due Pseudomonas aeruginosa ( PA ) .</brief_summary>
	<brief_title>Safety Efficacy Study Aztreonam Inhalation Solution ( AZLI ) Cystic Fibrosis ( CF ) Patients With Pseudomonas Aeruginosa ( PA )</brief_title>
	<detailed_description>People CF often lung infection occur repeatedly worsen time . The lung infection often cause PA . Treatment antibiotic use reduce presence bacteria . The antibiotic may give orally , intravenously , inhaled mist . The purpose study evaluate whether AZLI , investigational formulation antibiotic aztreonam , safe repeat course patient CF PA. A course AZLI treatment study comprise 28 day , follow 28-day period treatment . Participants could receive 9 course AZLI , total time study 18 month . Safety efficacy result 18-month , 9-course period report , efficacy result present by-treatment course basis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Compliance Studies CPAI005 ( NCT00104520 ) CPAI007 ( NCT00112359 ) take least 50 % expect study medication . Completion CPAI005 CPAI007 withdrawn due need antipseudomonal antibiotic AE unrelated study medication tolerance . Ability provide write informed consent/assent prior initiation studyrelated procedure . Ability perform reproducible pulmonary function test . Use investigational medication device last visit CPAI005 CPAI007 Visit 1 study . Concurrent participation study another investigational drug device . Current use oral corticosteroid dos exceed equivalent 10 mg prednisone/day 20 mg prednisone every day . History sputum throat swab culture yield Burkholderia cepacia previous 2 year . History daily continuous oxygen supplementation requirement 2 liters/minute night . Inability tolerate study medication CPAI005 CPAI007 . Known local systemic hypersensitivity aztreonam . Inability tolerate inhalation short act beta2 agonist . Abnormal renal hepatic function base result recent test . Female childbearing potential pregnant , lactating , ( opinion investigator ) practice acceptable method birth control . Any serious active medical psychiatric illness , opinion investigator , would interfere participant treatment , assessment , compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
</DOC>